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The molecular basis of T cell anergy is not completely
understood. We show that in antigen-primed anergic
murine CD4+ T cells the linker for activation of T cells
(LAT) is hypophosphorylated upon CD3/CD28 restim-
ulation. Signaling events downstream of LAT (PLCg1
phosphorylation and p85 [PI3-K] association) were im-
paired, whereas upstream events (CD3z and ZAP-70
phosphorylation) remained intact. LAT recruitment
to the immunological synapse and its localization in
detergent-resistant membrane (DRM) fractions were
defective in anergic T cells. These defects resulted
from impaired palmitoylation of LAT and were selec-
tive since the DRM localization and palmitoylation of
Fyn were intact. This LAT defect was independent of
Cbl-b and did not reflect enhanced LAT degradation.
These results identify LAT as themost upstream target
of anergy induction; moreover, they suggest that reg-
ulation of the amount of LAT in the immunological
synapse and DRM by posttranslational palmitoylation
contributes to the induction of T cell anergy.
Introduction
Engagement of the antigen-specific T cell receptor (TCR)
and costimulatory receptors initiates a complex signal
transduction cascade that involves protein kinases and
adaptor proteins (Samelson, 2002). Activation of Lck
kinase, followed by tyrosine phosphorylation of the
TCR-associated z chain and recruitment of ZAP-70,
leads to activation of ZAP-70, which then phosphory-
lates a key membrane adaptor protein, linker for activa-
tion of T cells (LAT) (Zhang et al., 1998a). Phosphorylated
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Kyushu University, Fukuoka 812-8582, Japan.LAT functions as a scaffold to recruit several signaling
molecules such as Grb2, Gads, phospholipase C-g1
(PLCg1), the p85 regulatory subunit of phosphatidylino-
sitol 3-kinase (PI3-K), and, indirectly, SLP-76. Analysis
of LAT-deficient mice and LAT-deficient Jurkat T cell
lines has further established its critical role in T cell de-
velopment and activation (Lin et al., 1999; Zhang et al.,
1999a, 1999b). LAT undergoes a posttranslational mod-
ification in the form of palmitoylation, which leads to
its localization in detergent-resistant membrane (DRM)
fractions (Shogomori et al., 2005; Zhang et al., 1998b).
This localization is essential for LAT signaling (Harder
and Kuhn, 2000; Lin et al., 1999; Zhang et al., 1998b,
1999a). Two pools of LAT distinguished by their palmi-
toylation (Zhang et al., 1998b) and intracellular localiza-
tion (Bonello et al., 2004) have been characterized by
fluorescence microscopy, suggesting that the function
and localization of LAT might be regulated by reversible
palmitoylation.
Clonal anergy represents one of several tolerance
mechanisms in T cells. T cell anergy was first observed
when an antigen-specific T cell clone was stimulated
with an antigenic peptide presented by chemically fixed
antigen-presenting cells (APCs) (Jenkins and Schwartz,
1987). T cell anergy is defined by defective proliferation
and IL-2 production by previously primed T cells upon
restimulation, and it is reversed by the addition of exog-
enous IL-2 (Beverly et al., 1992). Anergy does not reflect
a global failure of TCR signaling pathways but, rather,
a selective defect in activation of a subset of TCR-
induced signaling pathways. One key factor in anergy in-
duction seems to be an imbalance between Ca2+/NFAT
and AP-1 activation. Ca2+/NFAT mobilization in the ab-
sence of AP-1 signaling induces a genetic program of
lymphocyte anergy, which includes increased expres-
sion of Egr-2 and Egr-3, E3 ligases, and other proteins
(Anandasabapathy et al., 2003; Heissmeyer et al., 2004;
Macian et al., 2002; Safford et al., 2005). Nevertheless,
relatively little is known about aberrations in early, mem-
brane-coupled signaling events that can account for
the multiple downstream signaling defects in anergic
T cells.
During the course of analyzing proximal TCR signaling
events in anergic T cells, we found that TCR signaling is
markedly impaired at the level of LAT phosphorylation.
We demonstrate that in anergic T cells, LAT displays
grossly reduced localization in the immunological syn-
apse (IS) and in DRM fractions, which, in turn, results
from a selective defect in LAT palmitoylation. To our
knowledge, these results document a novel defect in
anergic T cells at the level of LAT palmitoylation, locali-
zation, and subsequent activation.
Results
TCR Signaling in Ionomycin-Anergized T Cells
In order to study changes in proximal signaling events in
anergic T cells, we induced T cell anergy by treating
primed TCR-transgenic (Tg) T cells with ionomycin ac-
cording to a well-established protocol (Schwartz, 2003;
Immunity
514Figure 1. Early T Cell Signaling Is Impaired at the Level of LAT in Anergic T Cells
(A–C) Antigen-primed control or ionomycin-treated (anergic) T cells were left unstimulated or were stimulated for (A and C) 1.5 min or for (B) the
indicated times by crosslinking with anti-CD3 plus anti-CD28 mAbs at 37ºC. (A–C) Lysates or (A) CD3z and (C) LAT immunoprecipitates were
subjected to immunoblotting.
(D) After extensive washing of control or ionomycin-treated cells, the cells were allowed to rest for 2 days and were stimulated as described in the
legend for (A), and SDS-PAGE-resolved CD3z immunoprecipitates or total lysates were immunoblotted.
(E) Control (C) or ionomycin-treated, anergic (A) T cells were allowed to rest for 2 days in the absence or presence of IL-2 (100 U/ml), stimulated by
CD3/CD28 crosslinking, and analyzed as described in (D).
Results in (A) and (B)–(E) are representative of four and two similar experiments, respectively.Macian et al., 2002), As expected, when antigen-primed
AD10 CD4+ T cells were cultured with ionomycin and re-
stimulated with APCs plus pigeon cytochrome c (PCC)
peptide 88–104, we observed a w60% and w80% re-
duction in proliferation and IL-2 production, respec-
tively; addition of exogenous IL-2 fully restored the
proliferation of the anergic T cells (data not shown).
Furthermore, in agreement with recent studies (Heiss-
meyer et al., 2004; Safford et al., 2005), the mRNA
expression of Cbl-b was increased by 2.4 6 0.5-fold
(mean6 SEM, n = 3) after ionomycin treatment, whereas
the mRNA expression of LAT remained unchanged. Phe-
notypic analysis of ionomycin-treated cells revealed no
change in the surface expression level of TCR, CD3,
CD4, CD28, CD45RB, and CD90 (data not shown).
Biochemical analysis of ionomycin-induced anergic
T cells revealed reduced tyrosine phosphorylation of
LAT (Y171 and Y191) and PLCg1 (Y783) after CD3/
CD28 restimulation (Figure 1A). To determine the selec-
tivity of this defect, we evaluated the phosphorylation of
other early signaling intermediates normally activated
by CD3/CD28 engagement. As shown in Figure 1A,
phosphorylation of CD3z and ZAP-70 (Y319 and Y493)
was not impaired in anergic T cells. The decreased
LAT phosphorylation did not reflect a change in the ki-
netics since analysis of LAT phosphorylation at different
time points after CD3/CD28 costimulation revealed that,
even though the tyrosine phosphorylation of LAT in aner-
gic T cells was somewhat delayed by comparison withcontrol T cells (peaking at 5 versus 1 min, respectively),
it was still substantially lower in magnitude at each
time point. In contrast, the extent and kinetic profile of
ZAP-70 phosphorylation was very similar in control and
anergic T cells (Figure 1B).
In order to determine whether the impaired phosphor-
ylation of LAT affects its ability to recruit essential down-
stream signaling intermediates in a phosphotyrosine-
dependent manner, we examined the association of
LAT with the regulatory (p85) subunit of PI3-K by coim-
munoprecipitation. Indeed, the association of p85 with
LAT was greatly reduced in the anergic T cells (Fig-
ure 1C). Since AD10 T cells were restimulated immedi-
ately after ionomycin treatment in the experiments
described above, it was possible that the reduced tyro-
sine phosphorylation of LAT reflected a transient effect
unrelated to the anergic state. To address this possibil-
ity, the ionomycin-treated T cells were washed and al-
lowed to rest for 2 days before restimulation. Under
these conditions, the tyrosine phosphorylation of LAT,
but not of ZAP-70 or CD3z, was still reduced (Figure 1D),
indicating that impaired tyrosine phosphorylation of
LAT is relatively stable. In addition, and consistent with
the proliferative response, the decreased phosphoryla-
tion of LAT in anergic T cells was largely restored by cul-
ture with exogenous IL-2 for 2 days (Figure 1E). Thus,
similar to conventional hallmarks of T cell anergy, the
observed LAT defect is both relatively stable and revers-
ible by IL-2.
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To confirm our findings in a biologically more relevant
model of T cell anergy, we induced T cell anergy by intra-
venous injection of soluble peptide into TCR-Tg mice
whose CD4+ T cells are specific for that same peptide
(Falb et al., 1996). Compared to control CD4+ T cells
from mice injected with PBS only, the proliferation (Fig-
ure 2A) and IL-2 production (Figure 2B) of CD4+ T cells
from PCC peptide-injected mice were reduced by
w55% andw88%, respectively.
Next, we analyzed the CD3/CD28-induced phosphor-
ylation of several relevant signaling molecules in these
in vivo-anergized T cells. In contrast to the tyrosine phos-
phorylation of CD3z and ZAP-70 (Y319), which was again
intact, the phosphorylation of LAT (Y191) and PLCg1
(Y783) was markedly reduced in the anergic T cells
(Figure 2C). These findings recapitulate the results ob-
tained with ionomycin-anergized cells and demonstrate
that reduced activation of LAT and PLCg1 in anergic T
cells is not restricted to the ionomycin-induced model
of T cell anergy, providing evidence that TCR signaling
is impaired at the level of LAT in anergic T cell in general.
Total LAT Expression, Cbl-b-Independent Reduction
of LAT Phosphorylation, and Intact CD28 Signaling
in Anergic T Cells
Induction of anergy has previously been shown to
change the expression of several proteins (Anandasaba-
pathy et al., 2003; Heissmeyer et al., 2004; Macian et al.,
2002; Safford et al., 2005). Several E3 ligases are upregu-
lated, whereas the expression of PKCq and PLCg1 is
reduced. Therefore, we explored in more detail whether
the expression of LAT is impaired in anergic T cells.
LAT mRNA expression was unchanged after anergy in-
duction with ionomycin (see above). LAT protein expres-
sion quantified by flow cytometry showed no difference
between control and anergic cells (Figure 3A). Likewise,
immunoblotting of RIPA buffer lysates from untreated
and ionomycin-treated T cells demonstrated no signifi-
cant reduction of LAT expression in the anergic T cells
(Figure 3B), excluding the possibility that under condi-
tions of solubilization in NP-40 lysis buffer, which were
used in other experiments (e.g., Figures 1 and 2), we
fail to detect a detergent-insoluble LAT pool whose ex-
pression is reduced in anergic T cells. These results also
practically rule out the possibility of reduced total cellular
LAT expression in anergic T cells due to, for example,
increased degradation. As reported previously (Heiss-
meyer et al., 2004; Jeon et al., 2004), ionomycin treat-
ment upregulated the expression of Cbl-b, whereas the
expression of Fyn or Grb2 was not affected (Figure 3B).
E3 ligases, which are upregulated in anergic T cells,
have been shown to be responsible for some changes
in signaling pathways of anergic T cells. To further ex-
clude the possibility that reduced LAT phosphorylation
is secondary to these effects, we treated primed CD4+
T cells from control and Cbl-b-deficient mice with iono-
mycin. As reported before, ionomycin increased the
expression of Cbl-b in control T cells; as expected, no
Cbl-b expression was detectable in Cbl-b2/2 mice (Fig-
ure 3C). CD3/CD28 costimulation induced LAT phos-
phorylation in both wild-type and Cbl-b2/2 T cells, which
were not pretreated with ionomycin. In both cases, how-
ever, increasing amounts of ionomycin similarly andgradually reduced LAT phosphorylation, demonstrating
that the impaired LAT phosphorylation in anergic T cells
is independent of Cbl-b.
CD28-derived costimulatory signals are important for
productive T cell activation and for the prevention of
anergy (Harding et al., 1992). These effects depend on
tyrosine phosphorylation of the CD28 cytoplasmic tail
and the recruitment of intracellular signaling proteins,
primarily PI3-K (Truitt et al., 1994). In addition, CD28 cos-
timulation also enhances the tyrosine phosphorylation
of LAT (Tsuchida et al., 1999). Therefore, we determined
whether CD28 signaling is impaired in anergic T cells.
When ionomycin-treated T cells were stimulated by
CD3/CD28 crosslinking, the tyrosine phosphorylation
of CD28 was not reduced by comparison with control,
untreated cells and, in fact, appeared to be increased
(Figure 3D, two upper panels). Similarly, there was no re-
duction in the amount of the PI3-K p85 subunit coimmu-
noprecipitating with CD28, and of p85 in total cell lysates
(Figure 3D, three lower panels). These data indicate that
CD28 signaling is largely intact in ionomycin-treated,
anergic CD4+ T cells.
Impaired IS Localization of LAT in Anergic T Cells
The development of a mature IS between T cells and
APCs is a key step in the events leading to full T cell
activation. Only recently, differences in the IS between
normal and anergized T cells have been described (Ise
et al., 2005). In agreement with these studies, we found
Figure 2. Functional Impairment and Decreased LAT Phosphoryla-
tion after In Vivo Anergy Induction
(A and B) Purified CD4+ T cells from AD10 mice injected with PBS
(open bars) or PCC peptide (closed bars) were stimulated with
PCC peptide plus irradiated syngeneic spleen cells for 3 days. (A)
Proliferation was assessed by [3H]thymidine uptake, and the mean
cpm of triplicate cultures 6 SD is shown. (B) The concentration of
IL-2 (mean 6 SD) in supernatants after 48 hr of culture was deter-
mined by an ELISA.
(C) Cell lysates or CD3z immunoprecipitates from PBS (control) or
PCC (anergic)-injected mice were left unstimulated or were stimu-
lated with crosslinked anti-CD3 plus anti-CD28 mAbs for 1.5 min,
and cell lysates were analyzed by immunoblotting. These results
are representative of three independent experiments.
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pendent Reduction of LAT Phosphorylation,
and Intact CD28 Signaling in Anergic T Cells
(A) Primed AD10 T cells were left untreated or
were treated with ionomycin. After washing,
the expression of LAT in control (solid line)
or anergic (broken line), fixed T cells was as-
sessed by flow cytometry. The shaded histo-
gram represents the negative control, which
was stained with normal rabbit IgG instead
of anti-LAT antibody. The results are repre-
sentative of two independent experiments.
(B) RIPA buffer lysates were prepared from
control or anergic T cells prepared as in (A),
and the lysates were analyzed by immuno-
blotting.
(C) Primed wild-type (+/+) or Cbl-b2/2 (2/2)
CD4+ T cells were cultured in the absence (0)
or presence of the indicated ionomycin con-
centrations, and, after washing, the cells
were stimulated with crosslinked anti-CD3
plus anti-CD28 mAbs for 5 min. Cell lysates
were analyzed by immunoblotting.
(D)PrimedT cells treatedwith (anergic) orwith-
out (control) ionomycin were stimulated with
crosslinked anti-CD3 plus anti-CD28 mAbs
for 5 min. Lysates (lower panel) or CD28 immu-
noprecipitates (four upper panels) were ana-
lyzed by immunoblotting. Similar results were
obtained in another independent experiment.no differences in conjugate formation between control
or ionomycin-treated T cells (data not shown). Next,
we analyzed the localization of LAT to the IS in anergic
T cells. Fluorescence microscopy experiments showed
that in peptide-stimulated control T cells, LAT colocal-
ized together with CD4 in the IS after incubation of
primed AD10 T cells with peptide-pulsed CH27 cells
(Figure 4). Pretreatment with ionomycin inhibited the lo-
calization of LAT in the IS, while CD4 remained concen-
trated in the IS. Thus, the anergic state is not associated
with a general displacement of IS-residing transmem-
brane proteins and is relatively selective for LAT.
Deficient DRM Localization of LAT in Anergic T Cells
TCR-activated ZAP-70 phosphorylates LAT (Zhang
et al., 1998a), and this event requires the localization ofLAT in DRM (Zhang et al., 1998b). Therefore, given the
impaired tyrosine phosphorylation of LAT in the face of
intact ZAP-70 activation, we examined the effect of ion-
omycin pretreatment on the constitutive association of
LAT with DRM. In unstimulated control cells, which
were not pretreated with ionomycin, a substantial frac-
tion of LAT (w23% by densitometry) was found in the
DRM (Figure 5A). However, the amount of LAT present
in the DRM of ionomycin-treated cells was greatly re-
duced (3% of total LAT). In contrast to LAT, the DRM
localization of Fyn (36% and 48% in the DRM fraction
of control versus ionomycin-treated cells, respectively)
and CD4 (6% and 13%, respectively) was not reduced
by ionomycin pretreatment, indicating that the impaired
raft localization of LAT in anergic T cells is selective and
does not globally affect raft-residing proteins. ThisFigure 4. Displacement of LAT from the IS in
Anergic T Cells
Primed control (first and third rows) or iono-
mycin-treated, anergized (second and fourth
rows) T cells were coincubated with PCC-
pulsed (upper two rows) or unpulsed (lower
two rows) APCs. Thereafter, cells were
stained with anti-CD4 antibody (green), anti-
LAT (red) antibody, and DAPI (blue). An over-
lay of green and red fluorescence is shown
in yellow. Differential interference contrast
(DIC) was used to show the cells and their
conjugates. The percentage 6 SEM of LAT-
positive conjugates was determined in three
independent experiments.
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517Figure 5. Displacement of LAT, but Not Fyn
or CD4, from the DRM in Anergic T Cells
(A) Primed AD10 T cells treated with (right
panel) or without (left panel) ionomycin were
lysed, and DRM and soluble fractions were
separated. The expression of phospho-LAT
(Y191), total LAT, Fyn, or CD4 in each fraction
was determined by immunoblotting.
(B) Pools of DRM or soluble fractions were
prepared from untreated control (C) cells or
from ionomycin-treated, anergic (A) T cells 2
days after ionomycin treatment. Pools as
well as total lysates were immunoblotted.
The results in (A) and (B) are representative of
four or two independent experiments, re-
spectively.reduction did not reflect a decreased amount of total
LAT since similar amounts of total cellular LAT protein
(Figures 3A and 3B) and mRNA (see above) were found
in control and anergic T cells.
The DRM localization of LAT, which depends on its
lipid modification as well as on protein-protein interac-
tions, is increased after T cell stimulation (Harder and
Kuhn, 2000; Zhang et al., 1998b). Therefore, we exam-
ined the status of LAT in DRM of anergized T cells after
restimulation. As expected, costimulation increased the
DRM localization of LAT, but even after CD3/CD28
crosslinking, LAT was still expressed at a lower level in
the DRM of anergic T cells than in unstimulated control
cells (Figure 5A). Moreover, the minor amount of LAT
in the DRM from anergic T cells was not detectably
phosphorylated on tyrosine. To address the possibility
that the reduced amount of LAT in the DRM from anergic
T cells reflected a decrease in the total amount of raft
lipids, we used flow cytometry to examine the expres-
sion of two lipid raft markers, GM1 and CD90 (Horejsi,
2003). Both markers were expressed at very similar
levels in control versus anergic T cells (data not shown),
indicating that both populations contained similar levels
of lipid rafts. Lastly, in order to assess the stability of this
LAT defect, we determined the distribution of LAT 2
days after removing ionomycin from the culture me-
dium. In conformance with the reduced LAT phosphory-
lation (Figures 1 and 5A), LAT was still depleted from the
DRM of anergic T cells 48 hr after ionomycin treatment
(Figure 5B). In contrast, the amounts of GM1 and Fyn
in the DRM pool were not reduced 48 hr after ionomycin
treatment.
Selectively Impaired LAT Palmitoylation
in Anergic T Cells
LAT is posttranslationally modified by palmitoylation (S-
acylation) via the covalent addition of palmitate to two
conserved membrane-proximal cysteine residues (C26
and C29) in its cytoplasmic domain (Zhang et al.,
1998b). The palmitoylation of LAT is essential for its par-
titioning into the DRM and for its proper function. There-
fore, we assessed LAT palmitoylation by labeling control
or anergic T cells with [3H]palmitic acid and by analyzingits incorporation into immunoprecipitated LAT. In aner-
gic T cells, the amount of radioactive palmitate incorpo-
rated into LAT was markedly decreased as compared to
that of control T cells, despite the fact that nearly equal
amounts of LAT were present in both immunoprecipi-
tates (Figure 6A, two upper panels). This decrease was
selective since [3H]palmitate incorporation into Fyn,
which is also a palmitoylated protein (van’t Hof and
Resh, 1999), was not affected by ionomycin treatment
(two lower panels). Furthermore, the dramatic and spe-
cific decrease in LAT palmitoylation was recapitulated in
in vivo-anergized TCR-Tg T cells (Figure 6B).
Figure 6. Reduced Palmitoylation of LAT in Anergic T Cells
(A) Antigen-primed AD10 T cells treated with (anergic) or without
(control) ionomycin were labeled with [3H]palmitic acid, and LAT or
Fyn were immunoprecipitated from the lysates. Aliquots were ana-
lyzed by fluorography and immunoblotting. These results are repre-
sentative of three independent experiments.
(B) T cells from PBS (control) or PCC peptide (anergic)-injected AD10
mice were labeled with [3H]palmitic acid and analyzed as described
in (A). These results are representative of three independent exper-
iments.
(C) Control (ctrl.) or anergic (iono) T cells were metabolically labeled
with [3H]palmitic acid as in (A) in the presence (+CHX) or absence
(2CHX) of cycloheximide. The palmitoylation of LAT was analyzed
as in (A) and was quantitated by densitometry analysis.
Immunity
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the reduced palmitate content of LAT in anergic T cells
could reflect its enhanced depalmitoylation and/or re-
duced (re)palmitoylation. To address this question,
anergic T cells were pretreated with cycloheximide in
order to block de novo LAT synthesis, and the palmitoy-
lation of LAT was compared in control and ionomycin-
treated T cells. Consistent with our previous findings
(Figures 6A and 6B), in the absence of cycloheximide,
the palmitate content of LAT was greatly reduced in ion-
omycin-treated cells. However, inhibition of protein syn-
thesis by cycloheximide treatment reduced the palmi-
toylation of LAT in control cells by 35%, whereas in
ionomycin-treated T cells, LAT palmitoylation was de-
creased by 60% (Figure 6C). These results indicate
that the (re)palmitoylation of preexisting LAT is impaired
in anergic T cells.
Discussion
The goal of this study was to identify molecules involved
in early TCR signaling whose functions are modulated in
anergic T cells. We chose to analyze two well-character-
ized anergy models in antigen-specific T cells, namely,
in vivo induction by intravenous injection of TCR-Tg mice
with an agonist peptide (Falb et al., 1996) and in vitro in-
duction by treatment of primed T cells with ionomycin
(Macian et al., 2002; Schwartz, 2003). The molecular
basis for ionomycin-induced T cell anergy was recently
elucidated by the demonstration that Ca2+ signaling
and NFAT activation in the absence of AP-1 activation in-
duces a gene expression profile characteristic of anergic
T cells (Macian et al., 2002). Indeed, both anergy induc-
tion protocols induced T cells that were anergic by sev-
eral criteria, i.e., reduced proliferation and impaired
IL-2 production, reversibility by exogenous IL-2, and,
lastly, increased expression of the E3 ligase Cbl-b (Heiss-
meyer et al., 2004).
Here, we demonstrate for the first time, to our knowl-
edge, that in both models of anergy, the most proximal
defect is at the level of LAT activation, as assessed by
its tyrosine phosphorylation and ability to recruit and ac-
tivate two of its immediate downstream targets (Figures
1 and 2C). However, more proximal signaling events, i.e.,
the Lck-mediated tyrosine phosphorylation of z chain
(Iwashima et al., 1994) and the activation of ZAP-70,
which directly phosphorylates LAT (Zhang et al., 1998a),
were intact in anergic T cells. These results are different
from the impaired ZAP-70 activation previously ob-
served in orally tolerized T cells (Asai et al., 2002) and
anergic Th2 cells (Faith et al., 1997). This apparent dis-
crepancy in ZAP-70 activity was recently evaluated,
and it was found that, whereas adaptive tolerant T cells
displayed reduced ZAP-70 activity, clonal anergic T
cells showed only minor impairment of ZAP-70 activa-
tion (Chiodetti et al., 2006). Activation of T cells by TCR
engagement (signal 1) in the absence of CD28 costimu-
lation (signal 2) can lead to T cell anergy (Harding et al.,
1992). Therefore, it was possible that CD28-induced sig-
naling is impaired in anergic T cells. Surprisingly, we
found that the TCR/CD28-induced tyrosine phosphory-
lation of CD28 and its association with PI3-K remained
intact in anergic T cells (Figure 3D). This result, which,
to the best of our knowledge, has not been reportedbefore, suggests that anergic T cells, at least those in-
duced by ionomycin, do not have an intrinsic defect in
their ability to respond to CD28 costimulatory signals.
Expression of E3 ligases is upregulated in anergic T
cells, leading to increased ubiquitination and degrada-
tion of several proteins involved in TCR activation
(Heissmeyer et al., 2004). However, our finding of normal
total LAT protein expression in anergic T cells (Figures
3A and 3B) essentially rules out the possibility of in-
creased E3 ligase-mediated LAT degradation being di-
rectly responsible for the observed LAT defects. Never-
theless, we cannot definitively exclude the possibility
that phosphorylation and/or palmitoylation of LAT affect
its degradation. At any rate, phosphorylation of LAT was
reduced in ionomycin-treated T cells from Cbl-b2/2
mice (Figure 3C), proving that the changes in LAT func-
tion are independent of this E3 ligase. Further studies
are required to explore in greater detail a potential rela-
tionship between hypopalmitoylation of LAT and in-
creased expression of E3 ligases as well as its potential
role in the induction and maintenance of anergy.
The impaired tyrosine phosphorylation of LAT in the
face of intact ZAP-70 activation suggested a defect in
the DRM localization of LAT. The DRM association of
LAT results from its palmitoylation on two membrane-
proximal cysteine residues, C26 and C29 (Zhang et al.,
1998b). This palmitoylation is considered to be essential
for the receptor-induced tyrosine phosphorylation and
function of LAT since palmitoylation-deficient, non-raft-
residing LAT mutants fail to become phosphorylated af-
ter TCR stimulation (Lin et al., 1999; Zhang et al., 1998b,
1999a). We found that anergy induction resulted in dis-
placement of LAT from the DRM, and that the reduced
DRM localization of LAT was maintained even after
TCR restimulation of the anergic T cells (Figure 5A).
This displacement was apparently sufficient to prevent
the TCR/CD28-induced tyrosine phosphorylation of
LAT and its ability to activate PLCg1 or recruit PI3-K (Fig-
ures 1 and 5A). DRMs are biochemically defined, and
their physiological relevance is somewhat controversial.
Therefore, we further examined whether the localization
of LAT in the IS is also impaired in intact anergic T cells.
Although T-APC conjugate formation per se was not re-
duced in anergic T cells (data not shown), in agreement
with a recent study (Ise et al., 2005), LAT (but not CD4)
localization in the IS was significantly inhibited (Figure 4).
One of the most surprising findings of our study was
the fact that the impaired DRM localization of LAT in
anergic T cells was selective, as indicated by the fact
the DRM localization of other palmitoylated molecules,
namely, the tyrosine kinase Fyn and the coreceptor
CD4, was unaffected. This result differs from previous
findings that polyunsaturated fatty acids (PUFA) block
TCR signaling by causing the displacement of LAT, as
well as other raft-residing signaling molecules such as
Src family kinases, from the DRM fraction (Stulnig
et al., 2001; Zeyda et al., 2002). This effect was attributed
to a change in the lipid composition of rafts (Stulnig
et al., 2001). In contrast, the selective displacement of
LAT (but not of Fyn and CD4) in our study indicates
that it almost certainly does not result from a global
change in the lipid composition of the rafts. Our results
also differ from reports that oxidative stress, as found
in synovial T cells from patients with rheumatoid
Defective LAT Palmitoylation in T Cell Anergy
519arthritis, suppresses LAT phosphorylation, reflecting its
displacement from the plasma membrane (Gringhuis
et al., 2000, 2002). This displacement was dependent
on cysteine residue C117 of LAT, which is not palmitoy-
lated. However, in our experiments, LAT was still pres-
ent in the membrane fraction after anergy induction, al-
though it failed to localize in the IS (Figure 4, and data of
subcellular fractionation experiments, not shown).
The defective DRM and IS localization of LAT in aner-
gic T cells was due to a marked defect in its palmitoyla-
tion even though its total cellular expression level re-
mained unchanged (Figures 3, 6A, and 6B). As in the
case of the reduced DRM localization, this defect was
selective since the steady-state palmitate content of
Fyn was unaffected in anergic T cells. This selectivity
suggests a specific decrease in the palmitoylation of
LAT or, conversely, its increased depalmitoylation. Sev-
eral groups have recently isolated two yeast PATs,
which were found to share a common domain termed
the CRD-DHHC domain (Lobo et al., 2002; Roth et al.,
2002) but to be otherwise unrelated (Linder and De-
schenes, 2004). Very recently, a large group of 23 murine
PATs, which display substantial substrate specificity,
has been isolated based on the presence of this CRD-
DHHC domain (Fukata et al., 2004). Therefore, one
intriguing explanation for our findings is that anergic
T cells display a defect in the expression and/or function
of a PAT, which has a relatively selective activity toward
LAT. This explanation is supported by the finding that
inhibition of protein synthesis by cycloheximide resulted
in greater reduction of LAT (re)palmitoylation in anergic
T cells than in control cells (Figure 6C). In addition,
a dominant-negative mutant of one PAT, which palmitoy-
lated LAT, was able to reduce LAT palmitoylation, DRM
localization, and phosphorylation (data not shown).
Another possibility is that expression and/or activity
of a palmitoyl protein thioesterase (PPT), which removes
covalently attached palmitoyl groups from LAT, may be
enhanced in anergic T cells. As only one cytoplasmatic
PPT, APT1, is known (Camp et al., 1994; Duncan and Gil-
man, 1998), and palmitoylation of Fyn in anergic T cells
was not impaired, it is unlikely that this might explain
the specific defect in LAT palmitoylation. Nevertheless,
future studies will have to address in more detail the
contribution of protein depalmitoylation to T cell respon-
siveness and, potentially, anergy.
The notion that reduced LAT palmitoylation is respon-
sible for its impaired function in anergic T cells appears
to be inconsistent with the recent finding that a nonpal-
mitoylated chimeric LAX/LAT protein, which consisted
of the intracellular domain of LAT fused to the trans-
membrane and extracellular domains of the adaptor
protein LAX, was fully tyrosine phosphorylated and
functional in stimulated T cells even though it was not
associated with lipid rafts (Zhu et al., 2005). This finding
suggests that besides palmitoylation, protein-protein in-
teractions may also be important for the proper local-
ization and function of LAT, as recently demonstrated
(Shogomori et al., 2005). However, a direct comparison
between intact LAT and the LAX/LAT chimera cannot
be made since quantitative or qualitative differences be-
tween the extracellular and transmembrane regions of
LAX and LAT, e.g., with regard to their association with
binding partners, may account for the apparent palmi-toylation-independent functionality of chimeric LAX/
LAT. Nevertheless, this LAX/LAT chimera might be a
valuable tool to investigate whether its forced expression
in T cells will render them resistant to anergy induction.
Previous studies identified TCR signaling abnormali-
ties in anergic T cells at several levels, including defects
in TCR tyrosine phosphorylation and expression or ac-
tivity of the Src family kinases Lck and Fyn (Boussiotis
et al., 1996; Gajewski et al., 1995; Quill et al., 1992; Salo-
jin et al., 1997), Ras and MAP kinase activation (DeSilva
et al., 1997; Fields et al., 1996; Li et al., 1996), activation
of the transcription factors AP-1 and NF-kB (Kang et al.,
1992; Mondino et al., 1996; Sundstedt and Dohlsten,
1998; Sundstedt et al., 1996), and excessive stimulation
of the negative regulatory small GTPase, Rap1 (Boussio-
tis et al., 1997), or an inhibitory Cbl-dependent pathway
(Boussiotis et al., 1996; Salojin et al., 1997). More recent
work identified abnormally high expression of Egr-2 and
Egr-3 (Safford et al., 2005) as well as several ubiquitin li-
gases, including GRAIL, Itch, and Cbl-b, the latter lead-
ing to increased degradation of their targets in anergic
T cells (Anandasabapathy et al., 2003; Heissmeyer
et al., 2004). However, it remains unclear whether all of
these abnormalities result from a single primary defect
or, rather, are independent events that combine to in-
duce and/or maintain the anergic state. Of interest, acti-
vation of PLCg1, Ras, MAP kinases, NF-kB, and AP-1,
which are all impaired in anergic T cells, is dependent
on intact LAT function (Finco et al., 1998; Lin et al.,
1999; Ouellet et al., 2003). Therefore, it is tempting to
propose that a selective defect in LAT palmitoylation
may be responsible for the impaired activation of these
critical signal mediators observed in anergic T cells.
Beyond raising intriguing questions regarding the
potential role of LAT palmitoylation in T cell anergy,
our findings suggest that functions of other palmitoy-
lated proteins in lymphocytes, e.g., CD4 (Balamuth
et al., 2004) and CD81 (Cherukuri et al., 2004), may
also be physiologically regulated by reversible palmitoy-
lation. Thus, further studies on the reversible palmitoyla-
tion of immunologically relevant receptors and signaling
proteins are likely to reveal a novel immunoregulatory
mechanism and potentially lead to new therapeutic pos-
sibilities. In conclusion, our study demonstrates that in
antigen-specific anergic T cells, TCR signaling was
blocked at the level of LAT, a result of its selectively im-
paired palmitoylation. Therefore, regulation of the palmi-
toylation status of LAT and other signaling proteins in
T cells by yet to be defined signals may modulate the
strength of TCR signaling and determine the functional
outcome of T cell triggering.
Experimental Procedures
Mice and Reagents
AD10 TCR-Tg B10.A mice expressing a TCR specific for PCC peptide
88–104 in association with I-Ek (Kaye et al., 1989) and Cbl-b2/2 mice
on a C57BL/6 background (Chiang et al., 2000) were bred and main-
tained in our animal facility. All animal experiments were performed
according to AAALAC guidelines and were approved by our IACUC.
Hamster anti-mouse CD33 (2C11), hamster anti-mouse CD28 (37.51),
and mouse anti-phosphotyrosine (4G10) monoclonal antibodies
(mAbs) were purified from hybridoma culture supernatants. Poly-
clonal rabbit anti-phospho-LAT (Y171 or Y191), anti-phospho-ZAP-
70 (Y319 or Y493), and anti-phospho-PLCg1 (Y783) were purchased
Immunity
520from Cell Signaling. The rabbit anti-LAT antibody for immunoprecip-
itation and immunoblotting was purchased from Upstate Biotechnol-
ogy, and the mouse anti-ZAP-70 and the rat anti-CD4 antibodies
were purchased from BD Biosciences. Mouse anti-CD3z mAb, goat
anti-CD28 and -CD4 antibodies, and rabbit anti-Fyn, -PLCg1,
-Grb2, -Cbl-b, or -PI3-K (p85 subunit) antibodies were purchased
from Santa Cruz. The secondary anti-hamster IgG used for crosslink-
ing was purchased from Pierce. Alexa Fluor 594-anti-rabbit Ig or
Alexa Fluor 488-anti-rat Ig antibodies and DAPI were obtained from
Molecular Probes. Aprotinin, leupeptin, PMSF, sodium vanadate,
ionomycin, cycloheximide, and HRP-conjugated cholera toxin B
subunit were purchased from Sigma.
Cell Culture, Priming, In Vitro Anergy Induction,
and Restimulation
Mouse lymph node and spleen cell suspensions were passed
through a T cell enrichment column (R&D Systems). CD4+ T cells
were enriched by negative selection by using a magnetic activated
cell sorting (MACS) system with rat anti-mouse CD8 and B220 anti-
bodies (BD Biosciences), followed by incubation with goat anti-rat
Ig-coated magnetic beads (Miltenyi). Over 95% of the resulting cells
were CD4+. Cells were cultured in 24-well plates (2.53 105 cells/well)
in a total volume of 2 ml culture medium (RPMI-1640 plus 10% FCS
including 10 mM HEPES, 1 mM sodium pyruvate, 50 mM 2-ME, 100
U/ml penicillin, and 100 mg/ml streptomycin) and were stimulated
with 0.5 mM PCC peptide plus irradiated (3000 rad) B10.A spleen
cells (2 6 106/well) as an APC source. A total of 11 days later, live
primed CD4+ T cells were enriched (R95% purity) by Ficoll-paque
(Amersham) centrifugation. The T cells were left untreated or treated
with 0.5 mM ionomycin for 16 hr. The cells were then harvested,
washed extensively, and incubated on ice for 20 min with anti-CD3
plus anti-CD28 mAbs (20 mg/ml each) or with control hamster IgG
(40 mg/ml). After washing, the cells were stimulated with a crosslink-
ing anti-hamster IgG antibody (20 mg/ml) at 37ºC for the indicated
times and were processed for biochemical or functional analyses.
In Vivo Anergy Induction
AD10 mice were injected twice, on days 0 and 3, intravenously in the
tail vein with 300 mg PCC peptide in PBS. On day 9, the mice were
sacrificed and CD4+ T cells were purified from the spleen and lymph
nodes as described above.
Proliferation Assay and IL-2 Measurement
After induction of anergy, T cells (33 104/well) were restimulated for
3 days with irradiated syngeneic spleen cells (53 105/well) plus 1 mM
PCC peptide in the absence or presence of exogenous IL-2 (100 U/
ml). Proliferation was assessed by [3H]thymidine uptake for the final
16 hr. IL-2 concentration in 48 hr culture supernatants was deter-
mined by a sandwich ELISA (matched antibody pair from BD Biosci-
ences) according to the supplier’s protocol.
Quantitative PCR
RNA was isolated from T cells with Trizol (Invitrogen) and transcribed
into cDNA with a SuperScript II Reverse Transcriptase Kit by using
random hexamer primers (Invitrogen) according to the supplier’s
protocols. Quantitative PCR was performed in a GeneAmp5700 (Ap-
plied Biosystems) with iTaq SYBR Green Supermix (Biorad) accord-
ing to the manufacturer’s protocol. PCR primer sequences were
retrieved from the online PrimerBank database (ID 25742730a1
[L32], ID 6754510a3 [LAT], and ID 26336995a1 [Cbl-b]) (Wang and
Seed, 2003). mRNA expression levels were corrected for primer
efficiencies and were normalized to the housekeeping gene L32
(Pfaffl, 2001).
Immunoprecipitation and Immunoblotting
Cells were washed with ice-cold PBS and resuspended for 15 min in
cold NP-40 lysis buffer (0.5% NP-40, 10% glycerol, 50 mM NaF, 10
mM Na4P2O7, 50 mM Tris-HCl [pH 7.0], 150 mM NaCl, 1 mM
PMSF, 2 mM Na3VO4, 1 mM EDTA [pH 8.0], and 10 mg/ml each apro-
tinin and leupeptin). Lysates were precleared with protein G-sephar-
ose (Amersham) and then incubated with the indicated antibody
(1 mg/sample) plus protein G-sepharose. After shaking at 4ºC over-
night, the complexes were washed four times with lysis buffer, and
the immunoprecipitated proteins were eluted with Laemmli buffercontaining 2-ME. Lysates or immunoprecipitates were separated
by SDS-PAGE and transferred to nitrocellulose membrane (Biorad).
After blocking with 5% (w/v) dry milk in Tris-buffered saline contain-
ing 0.1% Tween 20, the membrane was incubated overnight at 4ºC
with the indicated primary antibody, washed, and subjected to
chemiluminescence detection with HRP-conjugated anti-mouse or
-rabbit IgG antibody with ECL (all from Amersham). In selected ex-
periments, RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% DOC,
0.1% SDS, 50 mM Tris [pH 8.0], 1 mM PMSF, and 10 mg/ml each
aprotinin and leupeptin) was used instead of NP-40 lysis buffer to
ensure total solubilization of cellular proteins.
Flow Cytometry and Fluorescence Microscopy
Fixed T cells were stained with rabbit IgG (R&D Systems) or rabbit
anti-LAT (Cell Signaling) and were analyzed by flow cytometry.
CH27 B lymphoma cells, used as a source of APCs, were pulsed
with 0.5 mM PCC peptide for 2.5 hr at 37ºC and were washed. T cells
were then incubated with the pulsed APCs at a ratio of 1:1 at 37ºC.
After 15 min, the cells were transferred to poly-L-lysine-coated
slides. After adherence for 20 min, cells were fixed with methanol
for 10 min at 220ºC and washed with PBS. After blocking with
PBS/1% BSA for 30 min at room temperature, cells were incubated
with anti-LAT and anti-CD4 (1:200 each) antibodies for 1 hr. After
washing, the cells were labeled with Alexa Fluor 594-anti-rabbit Ig
or Alexa Fluor 488-anti-rat Ig antibodies (1:500 each) for 30 min,
then incubated with DAPI (0.5 mg/ml) for 5 min, and washed again.
Thereafter, slides were mounted with Vectashield (Vector) and
sealed with nail polish. Slides were examined with a Marianas digital
microscopy workstation with SlideBook software (Intelligent Imag-
ing Innovations). Images were deconvoluted by the nearest neigh-
bor method. For statistical analysis,w50 conjugates were evaluated
in each group.
DRM Isolation
T cells were lysed in 0.5 ml MNE buffer (25 mM MES [pH 6.5], 150 mM
NaCl, 5 mM EDTA, 30 mM Na4P2O7, 1 mM Na3VO4, and protease in-
hibitors) containing 1% Triton X-100 for 30 min on ice and were
dounced 15 times. Samples were centrifuged at 1000 3 g for 10
min at 4ºC. The supernatants were then mixed with 80% sucrose
(0.5 ml) and transferred to Beckman ultracentrifuge tubes. A total
of 3 ml 30% sucrose, followed by 1 ml 5% sucrose in MNE buffer,
was overlaid. Samples were ultracentrifuged in a Beckman
SW50Ti rotor (200,000 3 g for 18 hr at 4ºC). A total of 12 fractions
(0.4 ml each) were collected from the top of the gradient. Aliquots
from each fraction were separated by 10% SDS-PAGE and immuno-
blotted with the indicated antibodies.
Palmitoylation Assay
T cells (40 3 106/sample) were labeled for 3 hr with 0.5 mCi/ml
[3H]palmitic acid (Amersham) in RPMI-1640 containing 5% dialyzed
FCS and 5 mM pyruvate. The cells were harvested, washed, and
lysed in RIPA buffer. Cell lysates were immunoprecipitated with
anti-LAT or anti-Fyn antibodies, and immune complexes were ana-
lyzed by SDS-PAGE followed by fluorography or immunoblotting
with anti-LAT or anti-Fyn antibodies. For detection for labeled pro-
teins, gels were fixed in acetic acid (10% v/v) plus isopropanol
(25% v/v), incubated in Amplify Fluorografic Reagent (Amersham),
dried, and exposed to film at 280ºC for 1–2 months. To determine
palmitoylation of preexisting LAT in the absence of de novo protein
synthesis, new protein synthesis was blocked by incubation with cy-
cloheximide (50 mg/ml) for 1 hr. Thereafter, cells were labeled with
[3H]palmitic acid in the presence of cycloheximide for 3 hr.
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